S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Bangladeshi drugmaker acquiring country's Sanofi subsidiary

Thursday, January 21, 2021 | Julhas Alam, Associated Press

DHAKA, Bangladesh (AP) — A leading Bangladeshi drugmaker is acquiring a majority stake in French pharmaceutical giant Sanofi’s subsidiary in Bangladesh at a base price of more than $48 million, an official statement said late Thursday.

Sanofi, which has been in Bangladesh for more than 60 years as a top player in the pharmaceutical sector, said in 2019 that it wanted to leave Bangladesh. The reason was not clear, but industry insiders said it was difficult for the company to compete with other domestic players in the country's burgeoning pharmaceutical sector.

Beximco Pharmaceuticals, a Bangladeshi manufacturer and medicine exporter, said in a statement that it struck a deal with Sanofi to acquire the stake.

Sanofi Group holds nearly 55% of the shares in the paid-up capital of Sanofi Bangladesh. Of the remaining shares, over 25% are held by Bangladesh’s Ministry of Industries, while the government’s Chemical Industries Corporations owns nearly 20%.

Beximco said the acquisition is expected to be completed within the next three to nine months.

There are concerns that the departure of Sanofi would be a blow to foreign direct investment in Bangladesh, but Beximco thinks otherwise.

“This acquisition of Sanofi Bangladesh will serve as a strong foundation for sustainable growth in the future through strengthening our position in therapy areas where Sanofi has a strong footing,” Beximco’s managing director, Nazmul Hassan, said in the statement.

In addition to producing drugs, Sanofi has been involved in importing sensitive and high-tech products like vaccines, insulin and chemotherapeutic drugs directly from France, the United States, Britain and Germany.

While Sanofi and British partner GlaxoSmithKline are working to produce a coronavirus vaccine, the French company's subsidiary in Bangladesh is not involved.

Bangladeshi pharmaceutical companies get medicine exempted from patent protections and produce predominantly patent-expired and low-cost generic drugs because it’s a less developed country under the World Trade Organization.

The country exports medicine to about 150 countries, including some highly regulated markets in the European Union and Australia. The sector has an annual domestic market of about $3 billion.


15 Energy Stocks Analysts Love the Most

There are more than 450 energy companies traded on public markets. Given the sheer number of pipeline companies, power plant operators, oil and gas production companies, and other energy stocks, it can be hard to identify which energy companies will outperform the market.

Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 8,000 distinct recommendations for energy companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same energy stock.

This slide show lists the 15 energy companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

View the "15 Energy Stocks Analysts Love the Most".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.